50mg tirzepatide Tirzepatide – Lévis Peptides (PC)

Adults over 65 on GLP-1 drugs who face the highest risk of muscle loss, malnutrition, and bone complications include those who: Have any baseline indication of sarcopenia (reduced grip strength, slow gait speed, or prior falls) Are losing weight rapidly without concurrent resistance training Are not consuming enough protein, which may go unrecognized because reduced appetite from the drug masks inadequate nutritional intake Have kidney disease, osteoporosis, or other conditions that make lean mass and bone density loss more clinically consequential Are not being monitored for muscle and bone changes during treatment Symptoms and Warning Signs to Watch For Older adults on GLP-1 drugs and their family members should monitor for: Weakness that is disproportionate to weight loss (difficulty rising from a chair, reduced grip strength, or changes in gait) Significant fatigue or reduced energy that does not improve over time Falls or near-falls, which can be an early marker of functional muscle loss Inadequate fluid intake (dry mouth, decreased urination, confusion), which can indicate dehydration Unintended continuation of weight loss beyond a healthy target weight Signs of nutritional deficiency including hair loss, easy bruising, or oral health changes These symptoms should prompt contact with the prescribing physician and evaluation of protein intake, hydration, and body composition

Milovanovi M, Grujii R (2021) Electroencephalography in assessment of autism spectrum disorders: a review

Humphrey, A.C

Takeuchi T, Tanaka Y, Ishiguro N, Yamanaka H, Yoneda T, Ohira T, Okubo N, Genant HK, van der Heijde D (2016) Effect of denosumab on Japanese patients with rheumatoid arthritis: a doseresponse study of AMG 162 (Denosumab) in patients with rheumatoid arthritis on methotrexate to Validate inhibitory effect on bone Erosion (DRIVE)-a 12-month, multicentre, randomised, double-blind, placebo-controlled, phase II clinical trial